Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$45,117 | $22,499 | -$11,827 | $15,328 |
| Dep. & Amort. | $0 | $21,319 | $20,383 | $18,845 |
| Deferred Tax | $0 | -$7,162 | -$3,990 | -$72 |
| Stock-Based Comp. | $0 | $7,507 | $8,068 | $7,632 |
| Change in WC | $0 | $11,492 | $13,906 | -$5,129 |
| Other Non-Cash | $45,117 | $2,880 | $4,059 | $7,802 |
| Operating Cash Flow | $0 | $58,535 | $30,599 | $44,406 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$455 | -$327 | -$213 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | -$140,556 | -$118,557 | -$145,405 |
| Inv. Sales/Matur. | $0 | $110,404 | $156,201 | $132,980 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $0 | -$30,607 | $37,317 | -$12,638 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $0 | $3,276 | $2,042 | $6,877 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | -$2,341 | -$23,441 | -$987 |
| Financing Cash Flow | $0 | $935 | -$21,399 | $5,890 |
| Forex Effect | $6,660 | $0 | $0 | $0 |
| Net Chg. in Cash | $6,660 | $28,863 | $46,517 | $37,658 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $144,711 | $115,848 | $69,331 | $31,673 |
| End Cash | $151,371 | $144,711 | $115,848 | $69,331 |
| Free Cash Flow | $0 | $58,080 | $30,272 | $44,193 |